Shanghai Fosun Pharmaceutical Group Co Ltd (600196) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Fosun Pharmaceutical Group Co Ltd (600196) has a cash flow conversion efficiency ratio of 0.038x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥2.40 Billion ≈ $350.75 Million USD) by net assets (CN¥62.49 Billion ≈ $9.14 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai Fosun Pharmaceutical Group Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Shanghai Fosun Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Shanghai Fosun Pharmaceutical Group Co L balance sheet liabilities for a breakdown of total debt and financial obligations.
Shanghai Fosun Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Fosun Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beacon Roofing Supply Inc
NASDAQ:BECN
|
-0.070x |
|
One 97 Communications Limited
NSE:PAYTM
|
0.051x |
|
Nemetschek AG O.N.
XETRA:NEM
|
0.102x |
|
TURK HA.YO.UNS.ADR 10 TN1
F:TU5A
|
N/A |
|
Hoshine Silicon Ind Co Ltd
SHG:603260
|
0.006x |
|
Chang Hwa Commercial Bank Ltd
TW:2801
|
-0.061x |
|
Tripod Technology Corp
TW:3044
|
0.058x |
|
Indutrade AB
ST:INDT
|
0.093x |
Annual Cash Flow Conversion Efficiency for Shanghai Fosun Pharmaceutical Group Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Fosun Pharmaceutical Group Co Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see 600196 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥62.49 Billion ≈ $9.14 Billion |
CN¥6.01 Billion ≈ $878.76 Million |
0.096x | +28.64% |
| 2024-12-31 | CN¥59.93 Billion ≈ $8.77 Billion |
CN¥4.48 Billion ≈ $655.12 Million |
0.075x | -3.07% |
| 2023-12-31 | CN¥56.62 Billion ≈ $8.28 Billion |
CN¥4.36 Billion ≈ $638.48 Million |
0.077x | -1.13% |
| 2022-12-31 | CN¥54.11 Billion ≈ $7.92 Billion |
CN¥4.22 Billion ≈ $617.16 Million |
0.078x | -4.51% |
| 2021-12-31 | CN¥48.38 Billion ≈ $7.08 Billion |
CN¥3.95 Billion ≈ $577.83 Million |
0.082x | +45.50% |
| 2020-12-31 | CN¥45.98 Billion ≈ $6.73 Billion |
CN¥2.58 Billion ≈ $377.50 Million |
0.056x | -31.75% |
| 2019-12-31 | CN¥39.20 Billion ≈ $5.74 Billion |
CN¥3.22 Billion ≈ $471.54 Million |
0.082x | -6.40% |
| 2018-12-31 | CN¥33.59 Billion ≈ $4.92 Billion |
CN¥2.95 Billion ≈ $431.69 Million |
0.088x | +1.23% |
| 2017-12-31 | CN¥29.74 Billion ≈ $4.35 Billion |
CN¥2.58 Billion ≈ $377.57 Million |
0.087x | +3.82% |
| 2016-12-31 | CN¥25.25 Billion ≈ $3.69 Billion |
CN¥2.11 Billion ≈ $308.77 Million |
0.084x | +6.55% |
| 2015-12-31 | CN¥20.67 Billion ≈ $3.02 Billion |
CN¥1.62 Billion ≈ $237.21 Million |
0.078x | +24.82% |
| 2014-12-31 | CN¥19.10 Billion ≈ $2.80 Billion |
CN¥1.20 Billion ≈ $175.63 Million |
0.063x | +9.71% |
| 2013-12-31 | CN¥17.66 Billion ≈ $2.58 Billion |
CN¥1.01 Billion ≈ $148.03 Million |
0.057x | +31.70% |
| 2012-12-31 | CN¥15.30 Billion ≈ $2.24 Billion |
CN¥665.52 Million ≈ $97.39 Million |
0.043x | +56.15% |
| 2011-12-31 | CN¥11.37 Billion ≈ $1.66 Billion |
CN¥316.65 Million ≈ $46.34 Million |
0.028x | +28.63% |
| 2010-12-31 | CN¥9.39 Billion ≈ $1.37 Billion |
CN¥203.36 Million ≈ $29.76 Million |
0.022x | -42.52% |
| 2009-12-31 | CN¥6.95 Billion ≈ $1.02 Billion |
CN¥261.87 Million ≈ $38.32 Million |
0.038x | -28.14% |
| 2008-12-31 | CN¥4.45 Billion ≈ $650.58 Million |
CN¥233.04 Million ≈ $34.10 Million |
0.052x | +72.08% |
| 2007-12-31 | CN¥4.32 Billion ≈ $631.62 Million |
CN¥131.48 Million ≈ $19.24 Million |
0.030x | -39.90% |
| 2006-12-31 | CN¥3.65 Billion ≈ $533.90 Million |
CN¥184.91 Million ≈ $27.06 Million |
0.051x | -22.64% |
| 2005-12-31 | CN¥2.88 Billion ≈ $420.71 Million |
CN¥188.35 Million ≈ $27.56 Million |
0.066x | -10.12% |
| 2004-12-31 | CN¥2.81 Billion ≈ $411.75 Million |
CN¥205.10 Million ≈ $30.01 Million |
0.073x | -2.08% |
| 2003-12-31 | CN¥2.02 Billion ≈ $295.14 Million |
CN¥150.14 Million ≈ $21.97 Million |
0.074x | +21.56% |
| 2002-12-31 | CN¥1.67 Billion ≈ $244.87 Million |
CN¥102.47 Million ≈ $15.00 Million |
0.061x | +18.84% |
| 2001-12-31 | CN¥1.32 Billion ≈ $193.54 Million |
CN¥68.15 Million ≈ $9.97 Million |
0.052x | -54.64% |
| 2000-12-31 | CN¥1.22 Billion ≈ $178.30 Million |
CN¥138.43 Million ≈ $20.26 Million |
0.114x | +95.42% |
| 1999-12-31 | CN¥657.08 Million ≈ $96.15 Million |
CN¥38.20 Million ≈ $5.59 Million |
0.058x | -53.64% |
| 1998-12-31 | CN¥530.77 Million ≈ $77.67 Million |
CN¥66.55 Million ≈ $9.74 Million |
0.125x | -- |
About Shanghai Fosun Pharmaceutical Group Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumor… Read more